摘要
为了寻找对心肌缺血再灌注损伤具有保护作用的药物,以苯甲酰胍为母核,在其苯环的4位引入4-(2,3,4-三甲氧基苄基)哌嗪-1-甲基,3位引入不同的取代苯甲酰胺基,设计并合成了12个未见文献报道的目标化合物.其结构经MS,IR,1H NMR和元素分析确证.体外血小板肿胀模型(PSA)试验结果表明,大部分目标化合物显示出较好的Na+/H+交换器1(NHE1)抑制作用,其中化合物7g和7l抑制NHE1的IC50值分别为3.72和3.53nmol·L-1,是卡立泊来德(IC50=12.1nmol·L-1)的3.2和3.4倍.
In order to search for drugs with protective effect against myocardial ischernic-reperfusion injury, a novel series of 4-[4-(2,3,4-trimethoxy-benzyl)-piperazin-l-ylmethyl]benzoylguanidine derivatives were designed and synthesized from methyl 4-methyl-3-nitrobenzoate via bromination, substitution, reduction, acylation, hydrolyzation and condensation, and their structures were characterized by MS, IR, 1H NMR techniques and elemental analysis. Na+/H+exchanger 1 (NHE1) inhibitory activity of twelve compounds 7 was evaluated in a rat platelet swelling assay, and the results show that most of the tested compounds possess NHE1 inhibitory effects, among which, the ICs0 values of compounds 7g and 71 are 3.72 and 3.53 nmol·L^-1 respectively, making them 3.2 and 3.4 times respectively more potent than caripodde (IC50= 12.1 nmol·L^-1).
出处
《有机化学》
SCIE
CAS
CSCD
北大核心
2008年第12期2142-2148,共7页
Chinese Journal of Organic Chemistry
基金
国家自然科学基金(No.30672512)资助项目